The global monoclonal antibodies market is estimated to grow at a CAGR of 8.6% during the forecast period. An increasing number of trials for monoclonal antibodies for COVID-19 patients. For instance, in October 2020, Celltrion Group declared the introduction of its Phase III clinical trial investigating CT-P59. It is an anti-COVID-19 monoclonal antibody therapy candidate. The company estimates the enrolment of nearly 1,000 patients to assess population-based prophylaxis in contacts of SARS-CoV-2 infected patients. The prophylaxis post-exposure clinical trial will assess the safety and preventive effect of CT-P59 and whether CT-P59 can produce a counteracting antibody response for the prevention of virus from infecting human cells.
To Request a Sample of our Report on Monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/monoclonal-antibodies-market
Further, in August 2020, the National Institutes of Health (NIH) introduced a clinical trial that aims to test antibody therapy in hospitalized COVID-19 patients. Under the trial, COVID-19 patients at selected hospitals can volunteer in a clinical trial intended to test the efficacy and safety of an effective novel treatment for COVID-19. It is a Phase 3 randomized, controlled trial which is referred to as ACTIV-3, and as a master protocol. This is designed to test several diverse kinds of monoclonal antibody therapies. One of the major benefits of monoclonal antibody therapy is that it can particularly target the SARS-CoV-2 virus and this makes them more potential compared to other drugs.
Scope of the Global Monoclonal Antibodies Market
Market Coverage
- Market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Source and Application
- Regions Covered- North America, Europe, Asia-Pacific, and Rest of the World
- Competitive Landscape- Amgen Inc., Eli Lilly & Co., F- Hoffman La-Roche AG, Pfizer Inc., and Novartis AG
Recent Strategic Initiatives in the Global Monoclonal Antibodies Market
- In December 2019, Mylan N.V. and Biocon Ltd. declared the US FDA launch of Ogivri (trastuzumab-dkst). It is biosimilar to Herceptin (trastuzumab). It was the first biosimilar trastuzumab approved by the US FDA for all indications which includes treatment of HER2-overexpressing metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) and breast cancer.
- In June 2018, Pfizer Inc. announced the approval of ZIRABEV (bevacizumab-bvzr) in the US. It is a biosimilar to Avastin (bevacizumab) which is indicated to treat five kinds of cancer, including locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer, unresectable, metastatic renal cell carcinoma (RCC), recurrent glioblastoma; and persistent, recurrent or metastatic cervical cancer.
(Get 15% Discount on Buying this Report)
A full Report of Monoclonal Antibodies Market is Available at: https://www.omrglobal.com/industry-reports/monoclonal-antibodies-market
Global Monoclonal Antibodies Market-Segmentation
By Source
- Murine
- Chimeric
- Human
- Humanized
By Application
- Cancer
- Infectious Diseases
- Auto-Immune Diseases
- Inflammatory Diseases
- Others
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
